Table 1.

Characteristics of the studied cases

Parameters		Values		n
Age				105
	Median	62.0
	Years	30–81
Gender, n (%)				105
	Female	103 (98.10)
	Male	2 (1.90)
Histological grade, n (%)				103 and 2 mucinous carcinomas
	G1	2 (1.94)
	G2	47 (45.6%)
	G3	54 (52.43)
Histologic variant, n (%)				105
	NST (ductal)	85 (80.95)
	Invasive lobular carcinoma	13 (12.38)
	Mucinous	1 (0.95)
	Micropapillary	1 (0.95)
	Metaplastic	2 (1.90)
	Mixed (1 mucinous + NST and 1 metaplastic + mucinous)	2 (1.90)
	With medullary features	1 (0.95) (NST with lymphocyte rich stroma)
ypT stage, n (%)				105
	T0	12 (11.43)
	T1	22 (20.95)
	T2	47 (44.76)
	T3	8 (7.62)
	T4	12 (11.43)
	Tis	4 (3.81)
Lymph node status, n (%)				102 and 3 cases were Nx
	N0	32 (31.37)
	N1	31 (30.39)
	N2	26 (25.49)
	N3	13 (12.75)
Surrogate molecular subtype (defined by immunohistochemistry), n (%)		Luminal A 15 (15.46) Luminal B (High Ki-67/PgR negative) 45 (46.39)	Treated predominantly with epirubicin hydrochloride and cyclophosphamide	97 and 8 cases were not defined
		Luminal B (HER2 enriched) 7 (7.22) HER2 21 (21.65)	Treated with docetaxel; trastuzumab and pertuzumab
		Triple negative 9 (9.28)	Treated with paclitaxel and carboplatin
Steroid receptor positivity, n (%)				101 and 4 were uninterruptable due to artefacts
	ER positive	80 (79.21)
	ER negative	21 (20.79)
	PgR positive	66 (65.35)
	PgR negative	35 (34.65)
HER 2 status, n (%)				104 and one was uninterpretable
	HER2 positive	27 (25.96)
	HER2 negative	77 (74.04)
Lymphovascular invasion, n (%)				105
	Present	88 (83.81)
	Not evident	17 (16.19)
Surface occupied by tumour infiltrating lymphocytes, n (%)				99 and 6 have added acute inflammatory infiltrate
	0: < 1%	22 (22.22)
	1: 1–10%	34 (34.34)
	2: 11–49%	40 (40.40)
	3: > 50%	3 (03.03)

ER – oestrogen, HER2 – human epidermal growth factor receptor 2, NST – no special type (invasive ductal carcinoma), PgR – progesterone receptor